New research sheds light on how ketamine affects the brain by targeting a specific NMDA receptor subtype, GluN1-2B-2D.

Milestone payment triggered by the initiation of a Phase 2 clinical trial in Alzheimer’s disease with MK-1167, an α7 ...

This study presents solid evidence for distinct neurotransmitter release modalities between two subclasses of dopaminergic neurons in the olfactory bulb, highlighting an important finding that ...